CL2009000317A1 - Compuestos derivados de 3-alquil-piperazina sustituida; composicion farmaceutica; y su uso en el tratamiento de la depresion y ansiedad. - Google Patents
Compuestos derivados de 3-alquil-piperazina sustituida; composicion farmaceutica; y su uso en el tratamiento de la depresion y ansiedad.Info
- Publication number
- CL2009000317A1 CL2009000317A1 CL2009000317A CL2009000317A CL2009000317A1 CL 2009000317 A1 CL2009000317 A1 CL 2009000317A1 CL 2009000317 A CL2009000317 A CL 2009000317A CL 2009000317 A CL2009000317 A CL 2009000317A CL 2009000317 A1 CL2009000317 A1 CL 2009000317A1
- Authority
- CL
- Chile
- Prior art keywords
- anxiety
- piperazine
- depression
- substituted
- alkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Abstract
Compuestos derivados de 3-alquil-piperazina sustituida; composición farmacéutica; y su uso en el tratamiento de la depresión y ansiedad.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2897808P | 2008-02-15 | 2008-02-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2009000317A1 true CL2009000317A1 (es) | 2010-02-26 |
Family
ID=40521728
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2009000317A CL2009000317A1 (es) | 2008-02-15 | 2009-02-12 | Compuestos derivados de 3-alquil-piperazina sustituida; composicion farmaceutica; y su uso en el tratamiento de la depresion y ansiedad. |
Country Status (15)
Country | Link |
---|---|
US (1) | US7998963B2 (es) |
EP (1) | EP2254884B1 (es) |
JP (1) | JP2011512340A (es) |
KR (1) | KR20100101171A (es) |
CN (1) | CN101952278A (es) |
AR (1) | AR070415A1 (es) |
AU (1) | AU2009214190A1 (es) |
BR (1) | BRPI0908807A2 (es) |
CA (1) | CA2713378A1 (es) |
CL (1) | CL2009000317A1 (es) |
IL (1) | IL206951A0 (es) |
MX (1) | MX2010008778A (es) |
PE (1) | PE20091470A1 (es) |
TW (1) | TW200938533A (es) |
WO (1) | WO2009101018A2 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102753528A (zh) * | 2009-12-04 | 2012-10-24 | 霍夫曼-拉罗奇有限公司 | 作为单胺重摄取抑制剂的二苯基氮杂*衍生物 |
CN103508981A (zh) * | 2012-06-18 | 2014-01-15 | 北京美倍他药物研究有限公司 | 新的哌嗪衍生物及其医药用途 |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB950872A (en) | 1961-03-17 | 1964-02-26 | Soc Ind Fab Antibiotiques Sifa | Substituted pyridyl-ethyl-piperazines |
ES2203498T3 (es) | 1999-07-29 | 2004-04-16 | Eli Lilly And Company | Benzofurilpiperazinas: agonistas de receptor 5-ht2c de la serotonina. |
GB9926302D0 (en) * | 1999-11-05 | 2000-01-12 | Smithkline Beecham Plc | Novel compounds |
DE60102106T2 (de) * | 2000-08-03 | 2004-07-15 | Pfizer Products Inc., Groton | Diazacyclooctanverbindungen und ihre therapeutische Verwendung |
MXPA03007895A (es) * | 2001-03-02 | 2003-12-04 | Neurosearch As | Derivados novedosos de 2,5-diazabiciclo [2.2.1] heptano. |
MXPA03010612A (es) | 2001-05-22 | 2004-04-02 | Neurogen Corp | Ligandos receptores de la hormona concentradora de melanina: analogos de 1-bencil-4-aril piperazina substiruidos. |
JP4187642B2 (ja) * | 2001-06-07 | 2008-11-26 | エフ.ホフマン−ラ ロシュ アーゲー | 5−ht6受容体親和性を有する新規インドール誘導体 |
CA2445653A1 (en) * | 2001-06-11 | 2002-12-19 | Biovitrum Ab | Substituted sulfonamide compounds, process for their use as medicament for the treatment of cns disorders, obesity and type ii diabetes |
GB0119797D0 (en) | 2001-08-14 | 2001-10-03 | Glaxo Group Ltd | Chemical compounds |
PL209872B1 (pl) * | 2002-03-27 | 2011-10-31 | Glaxo Group Ltd | Pochodna chinolinowa, sposób jej wytwarzania i jej zastosowanie oraz zawierająca ją farmaceutyczna kompozycja |
JP2005289816A (ja) * | 2002-05-14 | 2005-10-20 | Banyu Pharmaceut Co Ltd | ベンズイミダゾール誘導体 |
WO2004080407A2 (en) | 2003-03-07 | 2004-09-23 | Predix Pharmaceuticals Holdings, Inc. | New serotonin modulating compounds and uses therefor |
WO2005023246A1 (en) * | 2003-09-04 | 2005-03-17 | Aventis Pharmaceuticals Inc. | Substituted indoles as inhibitors of poly (adp-ribose) polymerase (parp) |
US7582631B2 (en) * | 2004-01-14 | 2009-09-01 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
CA2556872C (en) * | 2004-02-20 | 2015-05-12 | Chiron Corporation | Modulation of inflammatory and metastatic processes |
JP4912145B2 (ja) * | 2004-02-26 | 2012-04-11 | あすか製薬株式会社 | ピリミジン誘導体 |
MXPA06014213A (es) * | 2004-06-18 | 2007-03-12 | Neurosearch As | Novedosos derivados de piperazina sustituidos por alquilo y su uso como inhibidores de la recaptacion del neurotransmisor monoamina. |
WO2006002464A1 (en) | 2004-07-01 | 2006-01-12 | Ringprop Trading Limited | Shroud or ring propeller blade interface |
JP4315393B2 (ja) * | 2005-04-14 | 2009-08-19 | 大塚製薬株式会社 | 複素環化合物 |
TWI320783B (en) * | 2005-04-14 | 2010-02-21 | Otsuka Pharma Co Ltd | Heterocyclic compound |
TWI329641B (en) * | 2005-08-31 | 2010-09-01 | Otsuka Pharma Co Ltd | (benzo[b]thiophen-4-yl)piperazine compounds, pharmaceutical compositions comprising the same, uses of the same and processes for preparing the same |
JP2009509964A (ja) * | 2005-09-23 | 2009-03-12 | メモリー・ファーマシューティカルズ・コーポレイション | インダゾール類、ベンゾチアゾール類、ベンゾイソオキサゾール類、ピラゾロピリジン類、イソチアゾロピリジン類、およびそれらの製造と用途 |
US7812162B2 (en) * | 2006-04-26 | 2010-10-12 | The University Of Montana | Enantiomers of 2′-fluoralkyl-6-nitroquipazine as serotonin transporter positron emission tomography imaging agents and antidepressant therapeutics |
WO2007137168A2 (en) * | 2006-05-18 | 2007-11-29 | Janssen Pharmaceutica N.V. | Bridged aryl piperazines derivatives useful for the treatment of cns, gi-urinary and reproductive disorders |
AU2007281678B2 (en) * | 2006-08-07 | 2012-08-02 | Albany Molecular Research, Inc. | 2-aminobenzoxazole carboxamides as 5HT3 modulators |
BRPI0715341A2 (pt) * | 2006-08-17 | 2013-11-26 | Hoffmann La Roche | Derivados de aril piperazina e usos dos mesmos |
TW200831498A (en) * | 2006-10-13 | 2008-08-01 | Otsuka Pharma Co Ltd | Heterocyclic compound |
JP4540700B2 (ja) * | 2006-10-13 | 2010-09-08 | 大塚製薬株式会社 | 医薬 |
JP4785881B2 (ja) * | 2007-02-27 | 2011-10-05 | 大塚製薬株式会社 | 医薬 |
-
2009
- 2009-02-05 EP EP09709926.1A patent/EP2254884B1/en not_active Not-in-force
- 2009-02-05 WO PCT/EP2009/051293 patent/WO2009101018A2/en active Application Filing
- 2009-02-05 MX MX2010008778A patent/MX2010008778A/es active IP Right Grant
- 2009-02-05 CN CN2009801050518A patent/CN101952278A/zh active Pending
- 2009-02-05 KR KR1020107017465A patent/KR20100101171A/ko active IP Right Grant
- 2009-02-05 AU AU2009214190A patent/AU2009214190A1/en not_active Abandoned
- 2009-02-05 JP JP2010546289A patent/JP2011512340A/ja active Pending
- 2009-02-05 CA CA2713378A patent/CA2713378A1/en not_active Abandoned
- 2009-02-05 BR BRPI0908807-5A patent/BRPI0908807A2/pt not_active IP Right Cessation
- 2009-02-12 AR ARP090100482A patent/AR070415A1/es unknown
- 2009-02-12 TW TW098104522A patent/TW200938533A/zh unknown
- 2009-02-12 CL CL2009000317A patent/CL2009000317A1/es unknown
- 2009-02-12 US US12/378,366 patent/US7998963B2/en not_active Expired - Fee Related
- 2009-02-13 PE PE2009000214A patent/PE20091470A1/es not_active Application Discontinuation
-
2010
- 2010-07-12 IL IL206951A patent/IL206951A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
AR070415A1 (es) | 2010-04-07 |
KR20100101171A (ko) | 2010-09-16 |
CN101952278A (zh) | 2011-01-19 |
CA2713378A1 (en) | 2009-08-20 |
EP2254884B1 (en) | 2013-05-01 |
BRPI0908807A2 (pt) | 2015-07-28 |
PE20091470A1 (es) | 2009-09-24 |
JP2011512340A (ja) | 2011-04-21 |
WO2009101018A3 (en) | 2010-01-28 |
WO2009101018A2 (en) | 2009-08-20 |
EP2254884A2 (en) | 2010-12-01 |
IL206951A0 (en) | 2010-12-30 |
MX2010008778A (es) | 2010-08-30 |
AU2009214190A1 (en) | 2009-08-20 |
US7998963B2 (en) | 2011-08-16 |
TW200938533A (en) | 2009-09-16 |
US20090209553A1 (en) | 2009-08-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2011000846A1 (es) | Compuestos heterociclicos sustituidos; composicion farmaceutica; y su uso para el tratamiento de la hepatitis c. | |
CL2011000527A1 (es) | Compuestos derivados de benzofurano; composicion farmaceutica que los comprende;y su uso en el tratamiento de la hepatitis c. | |
CL2011001333A1 (es) | Compuestos derivados de heterociclos nitrogenados sustituidos, inhibidores de ns5a; composicion farmaceutica; y su uso para el tratamiento de la hepatitis c. | |
CL2008002042A1 (es) | Compuestos derivados de heterociclos nitrogenados enlazados; y su uso en el tratamiento de la diabetes y desordenes metabolicos. | |
CL2009000119A1 (es) | Compuestos derivados de amino-bencimidazoles sustituidos; composicion farmaceutica; y su uso en el tratamiento del alzheimer. | |
CL2009000426A1 (es) | Compuestos derivados de carbociclil/heterociclil-piridin-2-il-urea, inhibidores de topoisomerasa iv bacteriana; composicion farmaceutica; y su uso para el tratamiento de infecciones bacterianas | |
CL2008001373A1 (es) | Compuestos derivados de fenilamino-benceno sustituidos; metodo de preparacion; composicion farmaceutica; kit farmceuticos; y uso de dichos compuestos en el tratamiento del cancer. | |
CL2009000349A1 (es) | Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer. | |
CL2009000200A1 (es) | Compuestos derivados de 2,7-naftiridinas-1-ona, mediadores de syk; composicion farmaceutica; y uso en el tratamiento de una enfermedad inflamatoria, respiratoria, proliferativa celular o autoinmune. | |
CR20110100A (es) | Nuevos derivados de sulfamida sustituida | |
CL2012002771A1 (es) | Compuestos derivados de ariletinilo sustituidos, moduladores de los receptores mglur5; proceso de obtencion; composicion farmaceutica; y su uso en el tratamiento o prevencion de la esquizofrenia, enfermedades cognitivas, sindrome de x fragil o el autismo. | |
ECSP10010722A (es) | Compuestos orgánicos | |
CL2012003026A1 (es) | Composicion farmaceutica que comprende pioglitazona y linagliptina; procedimiento de preparacion; uso en el tratamiento de la diabetes tipo 2 o la obesidad. | |
CL2008002295A1 (es) | Compuestos derivados de tiazolida sustituidos con alquilsulfonilos; composicion farmaceutica; y uso para el tratamiento de la hepatitis c. | |
CL2007002327A1 (es) | Compuestos derivados de fenil-imidazol sustituido; composicion farmaceutica; y uso en el tratamiento del vhc. | |
CL2008001633A1 (es) | Compuestos derivados de pirrolidin-3-carboxamida; composición farmacéutica; y uso comominhibidores de erk para el tratamiento del cancer. | |
BRPI0912717A2 (pt) | Composição farmacêutica, e, uso de 5-azacitidina | |
GT200800250A (es) | Arilimidazolonas y ariltriazolonas sustituidas como inhibidores de receptores de vasopresina | |
CL2007002207A1 (es) | Compuestos derivados de sulfonilaminas; composicion farmaceutica; y uso de los compuestos en el tratamiento del glaucoma. | |
CL2008001123A1 (es) | Compuestos derivados de acido lipoico; formulacion farmaceutica que lo comprende; y uso en el tratamiento del cancer. | |
CL2007001630A1 (es) | Compuestos derivados de pirrolidinamida; composicion farmaceutica; y uso para el tratamiento de la hepatitis c. | |
CL2007003672A1 (es) | Compuestos derivados de heteroaril-pirrolidinil-cetona y heteroaril-piperidinil-cetona; composicion farmaceutica; y uso en el tratamiento de la depresion y ansiedad. | |
CL2011001427A1 (es) | Compuestos derivados de 4-azetidinil-1-heteroaril-ciclohexanol; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como epoc, aterosclerosis, artritis reumatoide, entre otras. | |
EA201101116A1 (ru) | Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина | |
CL2012001757A1 (es) | Compuestos derivados de 8-hidroxiquinolina-7-carboxamida; composicion farmaceutica; y su uso en el tratamiento de infecciones micoticas. |